Thyrocare Releases Q2 FY27 Earnings Call Transcript
Thyrocare Technologies Limited released its Q2 FY27 earnings call transcript. The pathology business grew 27%, with a 4x increase in franchisees to 12,911. The company is divesting its radiology arm, NHL, for ₹141 crores. Consolidated revenue rose 25% YoY to ₹271 crores, with PAT up 26% YoY to ₹60 crores. Specialty diagnostics and new product launches are key focus areas.
The announcement includes a detailed earnings call transcript, providing insights into the company's financial performance, strategic decisions like the divestment of NHL, and future growth plans in specialty diagnostics, which are material to investors.
The company reported strong growth in its pathology business, significant expansion in its franchisee network, and a strategic divestment of its radiology arm. Financial performance showed robust revenue and profit growth, indicating a positive outlook.
Thyrocare Technologies Limited has released the transcript of its post-results earnings conference call held on October 29, 2026, with analysts and investors. The call featured management including MD & CEO Rahul Guha, CFO Vikram Gupta, and others, discussing the company's performance and strategic initiatives.
Key highlights from the call included the pathology business growing by 27% in Q2 FY27, driven by a 4x increase in the active franchisee base to over 12,911 and the opening of 5 new laboratories, expanding the network to 49 labs. The company is focusing on specialty diagnostics, including allergy and genomics, which currently contribute 4% of pathology revenue but are seen as a future growth engine. The disinvestment of its radiology business, Nueclear Healthcare Limited (NHL), to Trovera for ₹141 crores (₹81.9 crores cash, ₹59.5 crores equity) is underway, a strategic move to focus on the higher ROCE pathology business. Thyrocare also launched a pregnancy test kit, leveraging Yami Gautam as its brand ambassador and its sister concern Ascent for distribution.
Financially, consolidated revenue grew by 25% year-on-year to ₹271 crores in Q2 FY27, with consolidated gross margins at 74.2% and EBITDA margins at 33%. Profit after tax before exceptions stood at ₹60 crores, up 26% year-on-year. An impairment of ₹9 crores on standalone books and ₹45 crores on consolidated books was recognized against the goodwill of NHL. The company maintains a strong balance sheet with net cash and equivalents of over ₹211 crores and zero debt.
Management reiterated its commitment to providing affordable, high-quality diagnostics and serving as a B2B partner. Future plans include launching more point-of-care devices and expanding the specialty diagnostics portfolio, particularly in genomics and maternal screening.
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.